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SNHG5 promotes colorectal cancer cell survival
by counteracting STAU1-mediated mRNA
destabilization
Nkerorema Djodji Damas1, Michela Marcatti1, Christophe Coˆme1, Lise Lotte Christensen2,
Morten Muhlig Nielsen2, Roland Baumgartner1, Helene Maria Gylling1, Giulia Maglieri1,
Carsten Friis Rundsten1, Stefan E. Seemann3, Nicolas Rapin1, Simon The´zenas4, Søren Vang2,
Torben Ørntoft2, Claus Lindbjerg Andersen2, Jakob Skou Pedersen2 & Anders H. Lund1
We currently have limited knowledge of the involvement of long non-coding RNAs (lncRNAs)
in normal cellular processes and pathologies. Here, we identify and characterize SNHG5 as a
stable cytoplasmic lncRNA with up-regulated expression in colorectal cancer. Depletion of
SNHG5 induces cell cycle arrest and apoptosis in vitro and limits tumour outgrowth in vivo,
whereas SNHG5 overexpression counteracts oxaliplatin-induced apoptosis. Using an unbiased
approach, we identify 121 transcript sites interacting with SNHG5 in the cytoplasm. Impor-
tantly, knockdown of key SNHG5 target transcripts, including SPATS2, induces apoptosis and
thus mimics the effect seen following SNHG5 depletion. Mechanistically, we suggest that
SNHG5 stabilizes the target transcripts by blocking their degradation by STAU1. Accordingly,
depletion of STAU1 rescues the apoptosis induced after SNHG5 knockdown. Hence, we
characterize SNHG5 as a lncRNA promoting tumour cell survival in colorectal cancer and
delineate a novel mechanism in which a cytoplasmic lncRNA functions through blocking the
action of STAU1.
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A
berrant proliferation and increased cell survival are key
processes during malignant transformation and tumour
progression. To facilitate these processes, a number
of chromosomal rearrangements, mutations and epigenetic
modiﬁcations are typically selected for in cancerous cells,
resulting in an overall alteration of gene expression. Colorectal
carcinoma (CRC) is the third most common cancer worldwide1.
While invasive colorectal cancers that have not yet compro-
mised regional lymph nodes (stage I–II) have relatively good
prognoses with the current treatments and are curable in 73% of
the cases, the progression of the disease is fast and untreated
tumours rapidly disseminate to lymph nodes (stage III) and
metastasize to distant sites (stage IV)2. Thus, a better
understanding of the mechanisms driving the disease and
identiﬁcation of additional therapeutic targets is a priority for
improving CRC treatment3. Several studies have pointed to the
emerging roles of long non-coding RNAs (lncRNAs) in tumour
development, which could provide new candidates for diagnostics
and therapy.
Although mammalian genomes are widely transcribed, only
1–2% of the genomic output encodes for proteins4,5. Among
the large fraction of non-coding transcripts, the class of lncRNAs,
arbitrarily deﬁned as transcripts longer than 200 nts, is receiving
increasing attention and may present new opportunities
for cancer diagnosis and treatment. Although thousands of
lncRNAs have been identiﬁed, we still lack insight into the
structural–functional signiﬁcance of the vast majority of these
molecules in regulating fundamental cellular processes. However,
extensive gene expression and copy number variation analyses
have linked alteration of lncRNA expression to tumour
development. Resultantly, several lncRNAs, such as MALAT1,
HOTAIR, ANRIL, PVT1 and lincRNA-p21, have been reported
to play signiﬁcant roles in cancer initiation and development6–10.
In this study, we aimed to identify and characterize lncRNAs
functionally impacting on CRC. Proﬁling a large set of CRCs,
we identiﬁed the cytoplasmic lncRNA SNHG5 as signiﬁ-
cantly overexpressed in tumours. We provide evidence that
SNHG5 expression regulates the survival of CRC cells and the
progression of CRC tumour xenografts in a mouse model.
Importantly, whereas knockdown of SNHG5 prominently induces
apoptosis, SNHG5 overexpression can protect CRC cells from
oxaliplatin-induced apoptosis. While most of the hitherto
characterized lncRNAs function in the nucleus, much less is
known about lncRNAs and their mode of action in the
cytoplasmic compartment. A notable exception being competing
endogenous RNAs (ceRNAs), which act as molecular sponges for
microRNAs hence relieving repression of target mRNAs11,12.
Other known mechanisms for lncRNAs in the cytoplasm invo-
lve post-transcriptional regulation affecting mRNA stability or
accessibility to the translational machinery13. Through an unbia-
sed forward identiﬁcation of mRNAs interacting with SNHG5 in
the cytoplasm, we identify 121 interacting transcript sites in
HCT116 CRC cells. Importantly, loss of SNHG5 reduces the
protein levels of the interactors via destabilization of their
mRNAs. We further characterize the interaction of SNHG5
with the target SPATS2, and demonstrate that loss
of SPATS2 phenocopies the effect of SNHG5 depletion. STAU1
is a part of a highly conserved family of double-stranded
RNA-binding proteins implicated in mRNA transport, stability
and translation14–17. We show here that SNHG5 binding to target
mRNAs protects these from STAU1-mediated degradation.
Importantly, loss of STAU1 also rescues the apoptotic effect
of SNHG5 depletion.
Hence, we here provide new insights into the signiﬁcance of
lncRNAs in CRC in general and to the speciﬁc role of SNHG5 in
promoting CRC cell survival.
Results
SNHG5 is up-regulated in colorectal cancer. To identify
non-coding RNAs deregulated in CRC, we proﬁled their
expression in a cohort of 44 carcinomas, 39 adenomas, 20 adja-
cent normal mucosa and 10 CRC cell lines using a previously
described custom-designed microarray platform18. As expected,
the overall expression level of lncRNAs was lower than that of the
protein-coding genes in all sample sets (Supplementary Fig. 1a)19.
Among the most signiﬁcantly deregulated transcripts, we
identiﬁed several lncRNAs previously found deregulated in
cancer, such as ncRAN and GAS5, indicating the validity of our
approach (Supplementary Fig. 1b,c). We focus here on SNHG5
for which no function in CRC has been ascribed so far. RNA-seq
conﬁrmed the up-regulation of SNHG5 in CRC in a larger
independent cohort of 294 normal colon mucosa samples,
33 adenomas and 280 CRC samples (n¼ 313) (Fig. 1a). This
was conﬁrmed also restricting the analysis to the 268 paired
samples included in the same cohort (Supplementary Fig. 2a).
Interestingly, we ﬁnd SNHG5 to be signiﬁcantly up-regulated
both between normal tissues and adenomas, and from adenomas
to carcinoma stage I (malignant tumour), suggesting SNHG5
up-regulation as an early event in CRC development (Fig. 1b).
SNHG5 is composed of six exons spliced into two main
isoforms: the 1032 nts long SNHG5-1 and the shorter SNHG5-2
(430 nts) (Fig. 1c). SNHG5-2 is the most abundant isoform
expressed in CRC (Supplementary Fig. 2b), and we refer to it
as SNHG5 in the following experiments. Two snoRNAs, U50A
and U50B, are encoded in introns 4 and 5, respectively. We
proﬁled the expression of SNHG5 in a panel of human tissues and
found it most highly expressed in muscles, liver and
heart (Supplementary Fig. 2c). Reverse transcription (RT)–PCR
analysis revealed that the SNHG5 transcript, like many
other mRNA-like non-coding RNAs, is poly-adenylated
(Supplementary Fig. 2d). The SNHG5 transcript has a half-life
(t½) of 1 h, indicating an intermediate turnover rate when
compared with transcripts with a very short half-life, such
as MYC (t½¼ 30min), or more stable mRNAs, such as
ACTB (t½¼ 5–6 h) (Supplementary Fig. 2e). RNA ﬂuorescence
in situ hybridization (RNA-FISH) was performed using LNA
probes spanning the exon–exon junctions 3–4 and 4–5,
respectively, and showed SNHG5 to be predominantly cytosolic
in both HCT116 CRC cells and in immortalized TIG-3 human
ﬁbroblasts (Fig. 1d). This was also demonstrated by subcellular
fractionation studies and qRT–PCR (Fig. 1e). Polysome fractio-
nation studies showed a clear SNHG5 enrichment in the light, un-
translated fraction suggesting no association with ribosomes
(Supplementary Fig. 2f). In conclusion, we characterize SNHG5 to
be a stable and poly-adenylated ncRNA transcript not associated
with ribosomes and with an up-regulated expression in CRC.
SNHG5 affects proliferation and survival of CRC cells. Towards
identifying a function for SNHG5 we proﬁled its expression in a
panel of CRC cell lines (Supplementary Fig. 3a) and designed two
independent short interfering RNAs (siRNAs) targeting SNHG5
with knockdown efﬁciencies 475% (Fig. 1f). The cytosolic frac-
tion of the transcript was the most strongly reduced when
analysed 36 h after siRNA transfection (Supplementary Fig. 3b).
Moreover, the expression levels of the U50A snoRNA remained
unchanged, suggesting that the siRNAs target the spliced tran-
script and that phenotypic effects will be independent of the
snoRNAs, which in these cell lines exerts a nuclear restricted
expression (Supplementary Fig. 3c,d). To investigate biological
processes affected by SNHG5 depletion, RNA-seq was performed
in HCT116 cells 36 h after transfection with two indepen-
dent siRNAs against SNHG5 or a negative control siRNA
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(Fig. 1g). We found 150 genes to be signiﬁcantly deregulated by
both SNHG5 siRNAs (fold change 43, FDRo0.05). Gene
ontology analysis revealed a signiﬁcant enrichment of genes
involved in differentiation processes, such as mesoderm devel-
opment, cell communication and metabolic processes (Fig. 1h).
Furthermore, gene set enrichment analysis20 suggested that
SNHG5 depletion impacts key survival pathways in CRC cells,
such as the STAT3 pathway (Supplementary Fig. 3e). This was
further conﬁrmed using western blots for STAT3, a known
STAT3 target gene BCL-XL, and BCL-2 (Supplementary Fig. 3f).
Importantly, knockdown of SNHG5 (Supplementary Fig. 3g)
resulted in a strong anti-proliferative effect in CRC cells (Fig. 2a).
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Figure 1 | SNHG5 is deregulated in CRC. (a) The expression levels of SNHG5 were proﬁled in clinical specimens by RNA-seq, where the RNA was
extracted from tumour (C) or adjacent normal tissues (N) (****P valueo0.0001, Mann–Whitney t-test). (b) Box plot representing stratiﬁed SNHG5
expression in CRC clinical specimens (N¼ normal adjacent tissue, A¼ adenomas, I–IV¼CRC progression stages). The bottom line of each box represents
the 1st quartile of sample population, the top line of the box represents the third quartile, while the middle quartile represents the population median.
(***P valueo0.001, ****P valueo0.0001, Mann–Whitney t-test). (c) Schematic representation of the SNHG5 locus. (d) RNA-FISH of SNHG5 in red (Cy3)
with a nuclear DAPI stain (blue) in HCT116 and TIG-3 cells. Scale bar, 50mm. (e) RNA from the nuclear (N) and cytosolic (C) fractions were isolated from
HCT116 and TIG-3 cells and SNHG5 levels measured using qRT–PCR. U50A and ACTB were used as nuclear and cytosolic controls, respectively. The
expression values for each transcript are relative the total RNA input and normalized on the nuclear fraction expression levels. Error bars represent s.e. from
one representative experiment. (f) qRT–PCR. HCT116 cells were transfected with 50 nM siSNHG5-1-2 or control siRNA and the RNA collected after 36 h.
SNHG5 expression data are showed normalized to the GAPDH housekeeping gene and normalized to the non-targeting control siRNA. (g) Venn diagram
representing the number of genes altered in HCT116 cells following siSNHG5-1-2 transfection after 36 h (log2 fold change4 ±3, FDRo0.05).
(h) Gene ontology annotation. Statistical overrepresentation test (Bonferroni-corrected) was applied to identify gene categories affected by SNHG5
depletion.
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This result was conﬁrmed by cell cycle analysis using EdU
incorporation, which revealed a signiﬁcant decrease in the
S-phase cell population in SNHG5-depleted cells (Fig. 2b). To
investigate an impact of SNHG5 on survival, CRC cell lines were
stained for cleaved Caspase-3 protein and analysed by ﬂow
cytometry, which revealed a strong induction of apoptosis in both
HCT116, CACO-2 and DLD-1 cells (Fig. 2c, top). This was
conﬁrmed by western blots for cleaved PARP-1 (Fig. 2c, bottom).
As siRNA depletion studies may suffer from off-target effects,
we subsequently investigated the effect of SNHG5 overexpression.
Towards this, both a cDNA version (430 bp) and the entire
genomic locus of SNHG5 (1800 bp) were cloned (Fig. 2d)
and transiently expressed in HT-29 cells, which display a
lower endogenous SNHG5 level as compared with HCT116,
CACO-2 and DLD-1 cells (Supplementary Fig. 3a). Forty-eight
hour after transfection a 60-fold average increase in the SNHG5
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levels were detected by qRT–PCR in comparison to the empty
vector control (Fig. 2e, left). The cells were subsequently treated
for 24 h with oxaliplatin, a drug commonly employed in CRC
treatment. Interestingly, using ﬂow cytometry, we observed a
signiﬁcant decrease in the cleaved Caspase-3 positive population
of HT-29 cells overexpressing SNHG5 (Fig. 2e right). This
protective effect was evident for both the cDNA construct and the
entire SNHG5 locus, suggesting no signiﬁcance of the snoRNAs in
this assay. No proliferative effect was observed in HT-29 cells
overexpressing the SNHG5 lncRNA in the absence of drug
treatment (Supplementary Fig. 4a,b). Next, we created a panel of
SNHG5 mutants lacking individual exons and tested the ability of
these mutants to protect HT-29 cells from oxaliplatin-induced
apoptosis (Fig. 2f). Interestingly, whereas mutants for exons 2, 3,
5 and 6 all protected the cells to the same extend as full-length
SNHG5, mutants lacking either exon 1 or exon 4 failed to protect
against oxaliplatin-induced apoptosis (Fig. 2g).
We next employed a luminescent xenograft mouse model
to query whether SNHG5 expression is required for tumour
growth in vivo (Supplementary Fig. 4c). Luminescent HCT116
CRC cells holding doxycycline-inducible shRNAs targeting
SNHG5 or GFP as control were subcutaneously injected into
two groups of immune-compromised mice. To allow time for
tumour establishment, doxycycline was added to the drinking
water at day 13 after injection. SNHG5 levels were signiﬁcantly
reduced in the tumours following doxycycline treatment comp-
ared with the non-targeting control (Supplementary Fig. 4d).
Importantly, we observed a signiﬁcant negative effect on tumour
growth following SNHG5 depletion (Fig. 2h; Supplementary
Fig. 4e). SNHG5 depletion resulted in a signiﬁcant reduction of
tumour volume and weight as measured at the end of the
experiments at day 35 (Fig. 2i,j). Altogether, this data suggest that
SNHG5 expression functions to regulate proliferation and
survival of CRC cells both in vitro and in vivo.
RIA-seq identiﬁes primary downstream effectors of SNHG5.
Until now, only few mechanisms for cytoplasmic lncRNAs have
been revealed. To unveil the mechanism by which SNHG5 affects
proliferation and apoptosis in the cytoplasm, we used an unbiased
method, RIA-seq (RNA interactome analysis and sequencing), to
map transcriptome-wide RNA–RNA interactions21. Two sets
(Even and Odd) of eleven 30-biotinylated DNA oligonucleotides
were designed to speciﬁcally hybridize to SNHG5. A luciferase-
speciﬁc oligonucleotide pool was used as negative control
(Fig. 3a; Supplementary Fig. 5a). The pull-down efﬁciency was
estimated by qRT–PCR to B50% of the endogenous SNHG5
transcript pool in HCT116 cells (Fig. 3b). The interacting
RNA transcripts were identiﬁed using single-end 50 nucleotide
Illumina sequencing and the sequence reads were mapped
onto the Hg19 genome scaffold using the STAR aligner tool
(see ‘Methods’ section for details). The relative enrichment of
peaks present in both the Even and the Odd pools were calculated
with respect to the luciferase pool, which was used as back-
ground reference. We identiﬁed 121 signiﬁcant peaks overla-
pping between the Even and Odd pools (P valueo0.05)
(Fig. 3c; Supplementary Fig. 5b). About half of the peaks
mapped to coding regions (51.4%) while the majority of the
remaining peaks resided in 30 UTR regions (40%) (Supplementary
Fig. 5c).
We ranked a short list of SNHG5-interacting mRNAs based
on the number of peaks (overlapping and not-overlapping) in
each transcript and their local enrichment relative to
the luciferase background pool (Supplementary Fig. 5d). The
mRNA transcripts representing the peaks were subsequently
validated in HCT116 by qRT–PCR using peak-speciﬁc primers
(Fig. 3d; Supplementary Fig. 5d,e). We identiﬁed the SPATS2,
PITRM1 and GLE1 mRNAs as the most enriched SNHG5-
interacting transcripts. We further validated the RIA-seq data
in CACO-2 and DLD-1 cells, where SNHG5 depletion was also
found to affect cell survival (Fig. 2a). In these cells only the
interaction with the SPATS2 mRNA could be consistently
conﬁrmed, probably due to lower expression levels of the other
target transcripts in these cell lines (Supplementary Fig. 6a,b).
Importantly, SNHG5 depletion results in a clear decrease of
the target protein levels (Fig. 3e). To evaluate the effect of SNHG5
on the stability of the target transcripts, HCT116 cells
were treated for 5 h with the RNA PolII inhibitor Triptolide
following SNHG5 knockdown (Fig. 3f). The mRNA stabilities of
all three top interactors were reduced on SNHG5 knockdown as
quantiﬁed using qRT–PCR. Altogether, this data suggest that
SNHG5 forms RNA–RNA interactions with target mRNAs in the
cytoplasm and regulates their stability.
SPATS2 is a key downstream target of SNHG5. To further
explore the underlying mechanism, we focused on the SNHG5–
SPATS2 interaction and conﬁrmed that SNHG5 depletion in
Figure 2 | Manipulation of SNHG5 expression regulates proliferation and survival both in vitro and in vivo. (a) Proliferation assay. CRC cell lines were
transfected with 25 nM siSNHG5-1-2 or siControl. Cell numbers were assessed at the designated time points post transfection. Data normalized to the ﬁrst
time point are shown for the mean of 3 independent experiments. Error bars indicate±s.d. (*P valueo0.05, **P valueo0.01, Student’s t-test paired).
(b) HCT116, CACO-2 and DLD-1 cells were transfected as in a, pulsed with EdU after 36 h and analysed by ﬂow cytometry to measure the number of EdU-
labelled cells representing the S-phase populations. Data represents the mean of three independent experiments. Error bars indicate±s.e. (*P valueo0.05,
**P valueo0.01). (c) Top panel: CRC cell lines were transfected as in (a). Thirty-six hours after transfection, cells were labelled with cleaved Caspase-3
antibody and analysed by ﬂow cytometry. Data are shown for the mean of three independent experiments. Error bars indicate±s.e. (*P valueo0.05,
**P valueo0.01). Bottom panel: western blot analysis of endogenous cleaved PARP-1 levels in HCT116, CACO-2 and DLD-1 cells transfected with
siSNHG5-1-2 or siControl. GAPDH is included as loading control. A representative experiment is shown (n¼ 3). (d) Schematic representation of constructs
expressing the entire SNHG5 genomic (pSNHG5 locus) or only the cDNA (pSNHG5 cDNA). (e) Left, qRT–PCR. SNHG5 expression levels were measured
48 h after transfection into HT-29 cells. Data was normalized to the RPLP0 housekeeping gene and plotted relative to the empty vector control. Error bars
indicate the mean±s.e. of three independent experiments. Right, HT-29 cells were transfected with plasmids as described above. Forty-eight hours after
transfection the cells were treated with 25mgml 1 of oxaliplatin. Twenty-four hours later the cells were stained with cleaved Caspase-3 antibody and
analysed by ﬂow cytometry. Error bars indicate the mean±s.e. of three independent experiments. (*P valueo0.05, **P valueo0.01, ***P valueo0.01).
(f) Schematic representation of the SNHG5 cDNA expressing mutant plasmids. (g) Overall, 2 105 HT-29 cells were transfected with mutant plasmids and
treated with oxaliplatin as described above. Twenty-four hours later the cells were stained with cleaved Caspase-3 antibody and analysed by ﬂow
cytometry. Error bars indicate the mean±s.e. of three independent experiments. (*P valueo0.05, **P valueo0.01). (h) Xenograft growth of HCT116
pFULT-shGFP and HCT116 pFULT-shNHG5-4 cells. Doxycycline was added to the drinking water after 13 days. Mean±s.d. of tumor luminescence
(photons/seconds/cm2) at the indicated time points (for statistic analysis details see ‘Methods’ section). (i,j) Final volume and weight of tumours from the
experiment at day 35, respectively.
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HCT116, CACO-2 and DLD-1 cells, where both transcripts are
expressed at similar levels (Supplementary Fig. 6c), results in a
decrease of the SPATS2 protein levels (Fig. 4a). The SPATS2 gene
product is a predicted cytoplasmic RNA-binding protein, but
besides its potential involvement in the maturation of gonad cells
SPATS2 functions are unknown22. Importantly, SNHG5 over-
expression in HT-29 was found to increase SPATS2 protein levels
(Fig. 4b). An RNA–RNA interaction site was computatio-
nally predicted to span the ﬁrst exon of SNHG5 and the
30 UTR of SPATS2. Both the thermodynamics prediction
(Energy¼  15.50 kcalmol 1; IntaRNA) and the conservation
(PETcofold) point towards these regions as the interaction site.
The interaction is only conserved among primates (phylogenetic
tree predicted in PETcofold) and the phyloP base-wise
conservation (100 vertebrates UCSC genome alignment) shows
low evolutionary pressure on SNHG5 suggesting an evolutionary
new binding site (Fig. 4c). As expected, overexpression of SNHG5
promotes the stabilization of the SPATS2 mRNA (Supplementary
Fig. 6d). To identify the region in SNHG5 responsible for
promoting SPATS2 mRNA stability, we overexpressed the panel
of SNHG5 mutants and measured the stability of the SPATS2
mRNA following Triptolite treatment. Interestingly, the SNHG5
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mutant lacking exon 1 failed to promote SPATS2 mRNA stability
(Fig. 4d), thus sustaining the notion that SNHG5 interacts with
SPATS2 via elements in SNHG5 exon 1.
We then assessed the binding of SNHG5 to the 30-UTR of
SPATS2 (nts 2,456–2,660) using a luciferase reporter system
(Fig. 4e, top). The ectopic expression of SNHG5 in HEK293 cells
increased the luciferase activity of the SPATS2 30 UTR reporter
construct, as compared with the control, whereas the SNHG5
mutant lacking exon 1 was unable to do so (Fig. 4e, bottom). In
addition, we were able to compete the SNHG5 binding to the
SPATS2 30-UTR by co-transfecting the cells with a plasmid
vector expressing the full-length SPATS2 mRNA. In addition,
co-transfecting the full-length SPATS2 mRNA was also sufﬁcient
to compete the SNHG5 interaction with a second luciferase
construct containing the SNHG5 binding site from the GLE1
30-UTR (nts 2,496–2,706) (Supplementary Fig. 6e,f). Altogether,
these data demonstrate that SNHG5 can directly bind and
regulate SPATS2.
The SNHG5–SPATS2 axis promotes CRC cell survival. SPATS2
has not previously been implicated in cancer-related processes,
however, RNA-seq data analysis of CRC-paired samples showed
a signiﬁcant up-regulation of the SPATS2 transcript in tumours
versus correspondent normal tissues (Fig. 5a). Similarly, we
ﬁnd the two other top interactors GLE1 and PITRM1 to be
b
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up-regulated in CRC (Supplementary Fig. 7a). If the stabilizing
effect of SNHG5 on the SPATS2 mRNA is important for the
survival-promoting functions of SNHG5, we would expect loss of
SPATS2 to impact on CRC cell survival. Indeed, knockdown of
SPATS2 in CRC cell lines resulted in a signiﬁcant reduction of cell
viability (Fig. 5b; Supplementary Fig. 7b). Furthermore, pheno-
copying the effects observed on SNHG5 depletion, also the
inhibition of SPATS2 expression down-regulates the STAT3
pathway, hence conﬁrming the impact of SPATS2 expression on
viability in CRC cell lines (Supplementary Fig. 7c). Moreover,
ectopic SPATS2 expression in HT-29 cells prevented apoptosis
induction on oxaliplatin treatment, thus recapitulating the
SNHG5 overexpression phenotype (Fig. 5c).
To further explore the interaction between SNHG5 and
SPATS2, we investigated the SNHG5 and SPATS2 expression
patterns in primary CRCs and mouse xenograft tumours
(Supplementary Fig. 7d). The correlation found in CRC samples
was further conﬁrmed by analyzing SPATS2 levels in
the xenograft tumours, where knockdown of SNHG5 resulted
in a signiﬁcant decrease in SPATS2 mRNA levels (Fig. 5d).
Finally, we investigated whether restoring SPATS2 expression
in SNHG5-depleted CRC cells was sufﬁcient to rescue the
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apoptotic phenotype. Indeed, in HCT116 cells ectopic expre-
ssion of SPATS2-mediated a partial rescue from the anti-
proliferative and pro-apoptotic effect following the SNHG5
depletion (Fig. 5e–g). Altogether, this data suggest that the
SNHG5–SPATS2 interaction is important for promoting CRC cell
survival.
SNHG5 impairs the association of SPATS2 with STAU1.
We hypothesized that the binding of SNHG5 promoted SPATS2
mRNA stabilization via protecting the transcript from post-
transcriptional regulators. The RNA-binding protein STAU1 has
previously been described to destabilize mRNAs in the cyto-
plasm23. Interestingly, knocking down STAU1 resulted in an
up-regulation in both transcript and protein levels of SPATS2 in
HCT116 cells (Fig. 6a). To evaluate the effect of STAU1 depletion
on SPATS2 transcript stability and to compare with the effect
resulting from SNHG5 depletion, HCT116 cells were treated for
5 h with Triptolide following SNHG5 and STAU1 knockdown
(Fig. 6b). As expected, the SPATS2 mRNA stability was reduced
on SNHG5 depletion, whereas the opposite effect was measured
after STAU1 knockdown. To validate SPATS2 as a direct target of
STAU1, we performed RNA immunoprecipitation using a
STAU1 antibody after ultraviolet cross-link. Importantly, the
SPATS2 mRNA was enriched in the STAU1 pull-down compared
with the IgG control. Moreover, depleting SNHG5 in HCT116
cells increased the association of SPATS2 with STAU1. Impo-
rtantly, this was not observed for another known STAU1 target
gene, ARF1 (Fig. 6c)13. This data suggests that SNHG5 impairs
the association SPATS2 with STAU1. Having conﬁrmed SPATS2
as a key target of SNHG5, and STAU1 as a regulator of SPATS2,
we speculated if STAU1 could be implicated in CRC cell survival.
Towards this, we combined knockdown of STAU1 with
oxaliplatin treatment and measured the level of apoptosis.
As evident from Supplementary Fig. 7e, loss of STAU1 reduced
the level of apoptosis implicating STAU1 in CRC cell survival.
We queried the pathway hypothesizing that if SNHG5 and
STAU1 have opposite functions on SPATS2 mRNA stability,
loss of STAU1 might rescue the apoptosis seen following SNHG5
loss. Towards this, we combined the knockdown of SNHG5 and
STAU1 and measured the resultant level of apoptosis in HCT116
cells. As evident from Fig. 6d,e, loss of STAU1 expression strongly
reduced the apoptosis induction following SNHG5 depletion.
In conclusion, our analyses demonstrate that SNHG5 promotes
CRC cells survival by alleviating STAU1-induced degradation
of SPATS2.
Discussion
In this study, we used a customized array platform to proﬁle the
expression of lncRNAs in a set of CRC samples and to identify
lncRNA expression proﬁles correlating with disease progression.
We identiﬁed SNHG5 as signiﬁcantly up-regulated in CRC with
respect to normal tissues and validated this expression pattern
in an independent cohort of 313 CRCs. SNHG5 belongs to a
large family of non-coding genes hosting small RNAs, such as
snoRNAs and microRNAs, most often residing in the introns of
the host genes. Following excision of the small RNAs, these host
gene transcripts in general are unstable24, and many have been
viewed as biologically inert carriers, where the small RNAs are
thought to be the biologically relevant players25. Noticeable
exceptions include host genes such as GAS5, TINCR, ncRAN
and MIR31HG21,26–28, all of which have biological effects
independent of their hosted small RNAs. SNHG5 has not previ-
ously been characterized in CRC but was reported as a
translocation partner to BCL6 in a patient suffering from
diffuse large B-cell lymphoma29. SNHG5 encodes the snoRNAs
U50 and U500 in introns 4 and 5, respectively. Whereas snoRNAs
of the C/D box family are well-known to guide ﬁbrillarin-
mediated 20O methylation of the ribosomal RNA, reduced
expression and both somatic and germ line mutations in U50
have been reported from breast and prostate cancer30,31.
Furthermore, a non-canonical function of the U50 snoRNA in
modulating RAS activity was recently described32. Although
currently unclear, this is likely independent from the SNHG5
mechanism characterized in this paper.
We ﬁnd that SNHG5 expression levels are signiﬁcantly elevated
both in the transition between normal tissue and adenomas
and between adenomas and early stage (I) carcinoma. Impor-
tantly, suppression of SNHG5 expression not only exerts a strong
anti-proliferative effect and induces apoptosis, impacting key
survival pathways such as the STAT3 pathway in vitro, but also
reduces tumour progression in vivo. Moreover, SNHG5 over-
expression prevents apoptosis induction in CRC cell lines treated
with chemotherapeutic agents. We further characterize SNHG5 as
a stable, cytoplasmic lncRNA not associated with polysomes. This
prompted us to explore mechanisms for SNHG5 in the cytoplasm
by isolating mRNAs interacting with the lncRNA using RIA-seq.
This is in line with an increasing number of studies describing
post-transcriptional mechanisms of gene expression regulation
mediated by cytosolic lncRNAs22. We identiﬁed 121 signiﬁcant
sites of intermolecular interaction with SNHG5, located mainly in
cis-regulatory sequences (30 UTRs), and further pinpointed
SPATS2 as an important direct target of SNHG5 in multiple
CRC cell lines. SPATS2 is signiﬁcantly up-regulated in CRC
patients and knockdown of SNHG5 destabilizes the SPATS2
mRNA and signiﬁcantly reduces SPATS2 protein expression.
Vice versa, overexpression of SNHG5 leads to increased SPATS2
mRNA stability and protein expression. In vitro luciferase
reporter assays demonstrated that this effect is mediated via
direct interaction between a sequence motif in the SNHG5 exon
1 and the 30 UTR of SPATS2, although we cannot rule out other
interactions modes with other targets or in other cellular contexts.
Importantly, manipulating the expression levels of SPATS2
in CRC cells phenocopies the cellular viability response
following SNHG5 depletion or overexpression. Finally, restoring
the expression of SPATS2 in SNHG5-depleted cells resulted in
a partial rescue of the apoptotic phenotype induced by the
inhibition of lncRNA. Hence, SPATS2 is a key downstream target
of SNHG5. Interestingly, we ﬁnd that the expression levels
of SNHG5 and SPATS2 display a signiﬁcant negative correlation
in adenomas and xenograft tumours following SNHG5
knockdown, suggesting a contribution of the SNHG5–SPATS2
axis to tumorigenic events in CRC.
Several RNA-binding proteins have been described to regulate
mRNA stability and decay33. Here, we demonstrate in CRC cells
that the SNHG5–SPATS2 interaction impairs SPATS2-association
with STAU1, a major regulator of the cytoplasmic RNA decay.
STAU1 is part of a highly conserved family of double-stranded
RNA-binding proteins implicated in mRNA transport, stability
and translation; these processes depend on the ability of STAU1
to bind intra- or intermolecular RNA duplexes, most prominently
found in 30 UTRs of target mRNAs, and to recruit components of
the cytosolic decay machinery, such as UPF1 (ref. 13). STAU1 is
ubiquitously expressed, and whereas an important role for
STAU1 in the development of the central nervous system has
been described, the involvement of STAU1 in tumorigenic
processes remains largely unexplored. STAU1 has previously
been linked to lncRNA functions as a post-transcriptional
regulator of the stability of speciﬁc mRNAs involved in
epidermal terminal differentiation21,34 and cell cycle entry in
gastric cancer cell lines35. We analysed a recently published
hiCLIP dataset for STAU1 (ref. 17) and did not ﬁnd such sites
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in SPATS2. This, however, is unsurprising as that study was
performed in HEK293 cells in which SPATS2 is very lowly
expressed. Although we cannot rule out an impact of STAU1 on
SPATS2 translation, our data show that SPATS2 is sensitive to
STAU1-mediated mRNA decay and that SNHG5 can limit
the association of STAU1 to SPATS2. We also observe that
STAU1 knockdown rescues the apoptotic phenotype resulting
from SNHG5 depletion, thus demonstrating a genetic interaction
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between the SNHG5 and STAU1, promoting the stabilization of
SPATS2. An intriguing hypothesis is that the up-regulation
of SNHG5 during early stages of tumour progression may be
required in the transforming cells to buffer the STAU1-mediated
destabilization occurring on the SPATS2 mRNA, as well as other
target mRNAs, hence promoting the survival of the pre-cancerous
cells. Hence, inhibition of STAU1 decay activity on speciﬁc
mRNA target provides an intriguing hypothesis for important
early steps in CRC development but additional studies are needed
to evaluate the overall importance of this mechanism.
Altogether, our data describe a role of SNHG5 in regulating cell
survival in CRC and suggests SNHG5 as a potential candidate for
RNA-based anti-cancer drug studies.
Methods
Cell culture and animal experiments. HCT116, LS174T and HT-29 CRC cell
lines were maintained in McCoy’s medium
(Invitrogen) supplemented with 10% fetal bovine serum (Hyclone) and
penicillin/streptomycin (Invitrogen). CACO-2, and SW620 and HEK293 FT
cell lines were maintained in DMEM medium (Invitrogen) supplemented with
10% fetal bovine serum and penicillin/streptomycin. DLD-1 cell line was main-
tained in RPMI medium (Invitrogen) supplemented with 10% fetal bovine
serum and penicillin/streptomycin. Cell lines were obtained from the ATCC.
DNA plasmids were transfected at a ﬁnal concentration of 2.5 mgml 1 by
forward transfection using FuGENE HD Transfection Reagent (Promega, Fitch-
burg, WI, USA) according to manufacturer’s procedures. siRNA oligonucleotides
(listed in Supplementary Table 3) were transfected at a ﬁnal concentration of
50 nM by reverse transfection using RNAiMAX (Invitrogen), according to the
manufacturer’s instructions. Cells were treated with oxaliplatin (EIMC United
pharmaceutical) in aqueous solution at indicated concentrations and times,
where appropriate. For the RNA stability assay the cells were treated at the
indicated time points with 5 mgml 1 Actinomycin D or 10 mM Triptolide
(Sigma, St Louis, MO, USA). NMRI-nude adult females were obtained from
Janvier Labs. All mouse experiments were approved by Dyreforsøgstilsynet
according to Danish legislation (licence number 2012-15-2934-00306).
Tissue samples preparation and microarray analysis. The cancer specimens
included in this study are from the colorectal cancer biobank at the Department
of Molecular Medicine, Aarhus University Hospital. A total of 44 MSS and MSI
primary stage I–IV (T2-4, N0-3, M0/1) CRCs, 39 adenomas and 20 normal
colon mucosa samples were used in the array analyses. Finally, 280 fresh frozen
microsatellite stable (MSS) or microsatellite instable (MSI), primary stage I-IV
(T2-4, N0-3, M0/1) CRCs, 33 adenomas and 294 normal colon mucosa were
used for validation using RNA-seq. The samples were obtained directly from
surgery after removal of the necessary amount of tissue for routine pathology
examination. Patients who had received preoperative chemotherapy and/or
radiation of rectal cancers were excluded. Postoperatively, the tumours were
histologically classiﬁed and staged according to the TNM system. Cases with
hereditary colorectal cancer syndromes were not included in the study. The use
of the human tissue samples for research purpose was approved by the Central
Denmark Region Committees on Biomedical Research Ethics (DK; 1999/4678).
Informed written consent was given by all participants. RNA from both tissues
and cell lines was extracted using the RNeasy Mini kit following the manufacturer’s
instructions. The microarray platform and analysis was previously described18.
Arrays were normalized using the RMA implementation of the oligo software
package and subsequently analysed using the LIMMA package. For differential
transcript expression analysis, a linear model was ﬁtted to the expression data.
RNA-FISH. HCT116 and TIG-3 human ﬁbroblast were seeded and reverse
transfected with the indicated siRNAs in chamber glass slides (LAB-TEK).
Twenty-four hour after transfections, the cells were ﬁxed in 3.7% formaldehyde
(cat. 28906, Thermo Scientiﬁc, Rockford, IL, USA) overnight. Permeabilization
was carried out with 70% EtOH at 2–8 C for at least 60min followed by
30min incubation with 0.1M triethanolamine (Sigma)þ 0.5% (v/v) acetic
anhydride (Sigma) in water at room temperature (RT). The slides were
prehybridized for 1 h at 55 C with 100 ml of pre-hybridization buffer (50% for-
mamide (Sigma)þ 5 SSCþ 5 Denhardts solutionþ 0.5% Tween20
(Thermo scientiﬁc)). dFAM-labelled LNA-probes (Exiqon) were added to a ﬁnal
concentration of 20–30 nM in 100 ml of pre-hybridization buffer and incubated
at 55 C for 1 h in a humidiﬁed chamber. The slides were washed 3 10min in
0.1 SSC (Ambion) at 55 C, followed by 3 2min wash in 1 PBS (Gibco)
at room temperature and subsequently blocked in blocking buffer (10% heat
inactivated goat serum (cat. 34864, Sigma)þ 0.5% blocking reagent in PBS-Tween)
for 1 h at RT. For each slide 150 ml anti-FAM-POD diluted 1:40 in blocking
buffer was added and incubated for 1 h at room temperature. The slides were
washed twice 2min in 1 PBS and 50 ml Cy3-TSA substrate diluted 1:50 in
diluent and incubated in the dark for 10min at room temperature. Finally, the
slides were mounted with DAPI (Life Technologies) nuclear stain. The SNHG5
probe can be obtained from Exiqon.
Vector construction. We ampliﬁed the entire SNHG5 genomic locus
(±200 bp upstream and downstream the locus) by PCR (HiFi Platinum Taq,
Invitrogen) using the following primers: gSNHG5 FW 50-TACTGGCTGCG-
CACTTCG-30 , gSNHG5 RV 50-TACCCTGCACAAACCCGAAA-30 . The
amplicon was extracted from gel and cloned in pGEM T-Easy vector system
(Promega) and further subcloned into pcDNA 3.1(þ ) (Invitrogen). The
SNHG5 cDNA sequence was synthetically cloned in pUC57 backbone
(Genescript technology) and subcloned into pcDNA 3.1. The pSNHG5 cDNA
mutants were obtained using a Quickchange mutagenesis kit (Agilent) following
manufacturer’s instructions. The primers used for the mutagenesis are listed in
Supplementary Table 1. The lentiviral vector for the stable expression of SPATS2
cDNA (PLOHS_ccsbBEn_03998, GE Dharmacon) was used as template for
subcloning into pcDNA 3.1(þ ) backbone using the following primers:
SPATS2 cDNA forward EcoRI 50-GAATTCGTGGCTCTAGAAGGGGAG
GTGG-30 ; SPATS2 cDNA reverse EcoRI 50-GAATTCAATTAAATGC-
TACTTTCTCATAG-30 .
Crystal violet staining. Cells were seeded and reverse transfected in 6-well
plates. Twenty-four, forty-eight and seventy-two hour after transfection, cells
were washed twice in PBS (Gibco) and ﬁxed with 4% formalin (Sigma) for
10min, and stained with 0.1% crystal violet solution (Sigma). The amount of
crystal violet staining was quantiﬁed using the ‘ColonyArea’ ImageJ plugin
(Promega).
EdU incorporation assays. Cells grown in 6-well plates (NUNC) under appro-
priated conditions were pulsed with EdU (33 mM) for 20min before ﬁxation. The
EdU was detected using Click-IT EdU Alexa-Fluor 647 Flow Cytometry Assay Kit
(Molecular Probes, Life Technologies), according to the manufacturer’s protocol.
Data were obtained by ﬂow cytometric analysis of 15,000 cells per treatment and
analysed with the FlowJo 887 software (Tree Star, Ashland, OR, USA).
Cleaved Caspase-3 staining. Cells were reverse transfected using RNAiMax
reagent (Invitrogen) in six-well plates (NUNC). 36 h after transfection the cells
were harvested and ﬁxed in 4% formaldehyde methanol-free (Thermo Scientiﬁc)
and incubated for 30min on ice in 90% methanol in 1 PBS pH 7.4 (Gibco).
The cells were ﬁrst stained with anti-cleaved Caspase-3 antibody (#9664, Cell
signaling) in 1 PBS-2% BSA (Sigma) for 1 h at room temperature in the dark,
washed twice in 1 PBS-2% BSA and stained with Alexa-Fluor 647 goat anti-
rabbit secondary antibody (Life technology) for one additional hour at room
temperature protected from light. For propidium iodide staining, the labelled cells
were incubated in propidium iodide (Sigma) and RNase-A (Sigma) solution for
30min at 37 C. Data analysis was performed using the FlowJo 887 software.
Western blot analysis. Cells were seeded and reverse transfected in 6-well plates
(NUNC). After 36 h, cells were harvested, washed once with PBS and the pellets
lysed in RIPA buffer (150 nM NaCl, 0.1% sodium deoxycholate (Sigma), 0.1% SDS
(Sigma), 50mM Tris–HCl (pH 8), 1mM EDTA (Sigma)) containing protease
inhibitors (Complete Mini Protease Inhibitor Cocktail; Roche Applied Science).
Proteins were separated by electrophoresis in 4–12% NuPAGE Bis–Tris gels
(Invitrogen) and transferred to nitrocellulose membranes. The primary antibodies
used were: GAPDH (Santa Cruz, sc-25778), cleaved PARP-1 (Cell signaling, 5625),
PITRM1 (Pierce, PIEAPA531558), GLE1 (Abcam, ab69968), SPATS2 (Santa Cruz,
sc-390306), Bcl-xL (Cell Signaling, 2762), Bcl-2 (Cell Signaling, 2876), STAT3
(Cell Signaling, 9132) and STAU1 (Proteintech, 14225-1-AP). Un-cropped scans of
all western blots presented in the main ﬁgures are presented in Supplementary
Fig. 8.
Northern blot. Cells were seeded and reverse transfected in 6-well plates (NUNC).
After 36 h total RNA was isolated using Trizol reagent (Invitrogen). The RNA was
separated by electrophoresis in 10% TBE-Urea gel (Acrylamide 10%, TBE-Urea
7M, APS 1 , Temed 1 ) and transferred to nitrocellulose membranes
(Amersham). The membrane was cross-linked once at 120,000 mJ cm 2 with
Stratalinker UV Crosslinker (Stratagene). Pre-hybridization was carried out at
50 C for 1 h in Rapid hyb buffer (Amersham). The DNA probes were 32P-labelled
with T4 PNK kinase (New England Biolabs) and the hybridization carried out 1.5 h
at 50 C. The membrane were 20min in 50ml 5 SSC, 0.1% (w/v) SDS at room
temperature and 2 15min in 50ml 1 0.1 SSC, 0.1% (w/v) SDS at 50 C. The
probe signal was detected using FujiFilm Fluorescent Image Analyzer FLA-3000.
DNA probes used were as follows:
U50 50-TATCTCAGAAGCCAGATCCG-30 ; The RNU6B probe was obtained
from Exiqon.
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Cell fractionation. Cells were grown in 15 cm dishes (NUNC). For each sample
1 million cells were harvested and the nuclear/cytoplasmic fractionation was
performed using Nuclei EZ Lysis Buffer (Sigma), following the manufacturer’s
protocol. In the SNHG5 siRNA pool knockdown experiments HCT116 cells were
harvested 36 h after transfection using RNAiMax (Invitrogen).
RNA extraction and qRT–PCR analysis. Total RNA was isolated using Trizol
reagent (Invitrogen), treated with TURBO DNase (Ambion, Life Technologies)
and reverse transcribed using TaqMan Reverse Transcription kit (Applied
Biosystems) using random hexamer primers. QRT–PCRs were performed using
Sybr Green PCR Fast PCR Master Mix 2 (Applied Biosystems). The house-
keeping genes RPLP0, HPRT1 and GAPDH were used for normalization of
qRT–PCR data, unless otherwise stated. The primers used are listed in
Supplementary Table 1.
RNA sequencing. HCT116 cells were reverse transfected with All-star negative
control (Qiagen), siSNHG5-1 or siSNHG5-2 for 36 h in 6-well plates (NUNC).
RNA was extracted from three biological replicates, the quality assessed on the
2100 expert Bioanalyzer (Agilent) and sent for library preparation and
sequencing on the Illumina Hiseq2000 by BGI Genomics (Hong Kong).
In vitro transcription and copies number quantiﬁcation. Templates
containing the T7 promoter were generated by PCR with high-ﬁdelity DNA
polymerase Platinum Taq (Invitrogen). PCR products were puriﬁed from agarose
gels and 250 ng of template was in vitro transcribed using T7 RNA polymerase
and the MAXIscript kit (Ambion, Life Technologies) for overnight at 37 C.
After 30min DNAse treatment with TURBO DNA free at 37 C, the reactions
were stopped by adding 0.5mM EDTA. The concentration of the transcript
was measured by A260 values and converted to the number of copies using
the molecular weight of the RNA. Dilutions of this transcript were retro-tran-
scribed as described above and the complementary DNA was used as
standard curve for qPCR. The primers used for qPCR are: SPATS2 T7
forward 50-GGATCCTAATACGACTCACTATAGTAGAAGGGGAG
GTGGAGGAT-30; SPATS2 T7 reverse 50-GGATCCGCATTGGGCATTTTG
AAGAA-30 ; SNHG5 T7 forward 50-GGATCCTAATACGACTCACTATA
GCGGGTGGTAGGAACAATGG-30 ; SNHG5 T7 reverse 50-GGATCCTTT
CATGTTTGTAAAACGAAGAGC-30 .
Luciferase assay. Luciferase reporter constructs containing regions of the SPA
TS2 (NM_001293286.1) and GLE1 (NM_001003722) 30 UTRs were cloned into
pMIR-REPORT ﬁreﬂy luciferase vector (Ambion). pRL-Tk Renilla luciferase
reporter was used as transfection control and luciferase assay normalization.
The assays were performed 48 h after transfection of the indicated constructs
into 2.4 104 HEK293 cells per well (four wells each samples) seeded in 96-well
plates. The cells were transfected with 50 ng of ﬁreﬂy luciferase vectors and 1 ng of
the pRL-Tk Renilla reporter. The ﬁreﬂy reporters were competed by co-transfecting
50 ng of pcDNA 3.1 (þ ) expressing the SPATS2 cDNA. The reporter activities
were measured using the Dual Glo Luciferase assay System (Promega) and
GloMax Multi Detection System (Promega). The following primers were used
for the fragment subcloning PmeI–HinIII into pMIR-REPORT: SPATS2 30 UTR
forward PmeI primer 50-GTTTAAACGCCTCTATCCCAGAATGTGC-30 and
reverse HindIII primer 50-AAGCTTTGCTACTTTCTCATAGACTTCCCTA-30;
GLE1 30 UTR forward PmeI primer 50-GTTTAAACCCTCCCTTGTCTC-
TAGTGTCTT-30 and reverse Hind III primer 50-AAGCTTCAACCATAACCCA-
GACTTGCAT-30 .
In vivo imaging acquisition to follow tumour development. A luminescent
variant of the HCT116 cell lines were generated by transduction with the
pFULT lentiviral vector containing the luciferase2-tdTomato cassette as described
before36. The shRNA expressing cassettes harbouring a Tet-inducible promoter
were generated as described previously by other labs37. Two millions freshly
harvested cells from these shRNA subclones (200 ml from a stock solution of
10 millions cells per ml of PBS) were subcutaneously injected into the right
ﬂank of 22 weeks old NMRI-nude adult females (Janvier Labs). Tumour growth
was measured based on the luminescent signal using the IVIS Lumina II system
(Perkin Elmer), every 2–4 days from 1 week after cells injection. Mice were treated
with doxycycline (ad libitum, active compound diluted in drinking water at
2.5mgml 1, from Piggidox powder, Boehringer Ingelheim) when shGFP tumours
reached an average of 100mm3. The doxycycline solution was changed every 2–3
days until the end of the experiment. The shRNA sequences are listed in
Supplementary Table 3.
RNA interactome analysis and sequencing. HCT116 cells were collected
(30 million per sample) and resuspended in 20ml of PBS containing 1%
Glutaraldehyde (Sigma) for 10min at room temperature rotating. Glutaraldehyde
was quenched with 2ml of 1.25M Glycine (Sigma) (1/10 total volume) for
5min. The cell pellets were lysed in 2ml lysis buffer (Tris–Cl pH 7 50mM,
EDTA RNAse-free 10mM, SDS 1%, PMSF 1 , protease inhibitor cocktail,
Superase-In (Invitrogen)) and sonicated four times (25 cycles each, high pulse
3000 ON–4500OFF) using a BIORUPTOR (Diagenode). Cell lysates were centrifuged
for 20min @at 4 C 16,100g and the supernatant aliquoted for the immuno-
precipitation. The lysates were pre-cleared for 30min at 4 C with 50ml Dyna-
beadsMyOne Streptavidin C1 (Life Technologies) in 2ml of Hybridization
solution (NaCl 750mM, SDS 1%, Tris–Cl pH 7 50mM, EDTA 1mM, formamide
15%, PMSF 1 , protease inhibitor cocktail, Superase-In, yeast RNA (Ambion)
0.1mgml 1). One ml of hybridization buffer containing 100 pmol of probes
per ml of lysate was added to each sample and incubated for 4 h at 37 C rotating.
In parallel, the beads for the immunoprecipitation were blocked in hybridization
solution 30min at 4 C. We added 100ml of beads per 100 pmol of probes
and incubated rotating 30min at 37 C. The samples were washed ﬁve times
(5min each) in 1ml washing buffer (2 SSC, SDS 0.5%, PMSF 1 ) at 37 C
rotating. Each sample was Proteinase K (Invitrogen) treated for 45min at 50 C
shaking before RNA was extracted. A total of 150 ng from each sample were
sent for library preparation and sequencing on the Illumina Hiseq2000 at BGI
Genomics (Hong Kong) using Truseq protocol. Primers and biotinylated
probes sequences used for the pull-down and experiment validation are listed
in Supplementary Tables 2 and 3, respectively.
RIA-seq bioinformatics analysis. Trimming. The short reads were trimmed
using cutadapt to remove errors such as, for example, trailing adapter sequences.
The following deviations from default were used: error-rate¼ 0.05, minimum-
length¼ 25, overlap¼ 4, quality-cutoff¼ 20 as well as a list with the relevant
Illumina adapter sequences given to the ‘-a’ option.
Mapping. Because the reads were generated from a mixture containing post-
spliced mRNA, it was necessary to use a mapping approach that takes splice
junctions into account. We used the STAR aligner with default options except for
outFilterMismatchNoverLmax¼ 0.1 and outFilterMatchNmin¼ 16.
Peak calling. Peak calling was accomplished using the MACS2 algorithm with
the following non-default options: P¼ 1e 3, to-large, nomodel and shiftsize¼X,
where ‘X’ (the peak shift) was estimated individually for each sample using the SPP
programme. The fLUC samples were pooled and used as reference background.
The IDR algorithm was used to post-process the MACS2 results and to estimate the
number of reproducible peaks from the two ODD sample replicates. Owing to a
failed replicate, however, the IDR algorithm could not be applied to the EVEN
condition, and instead the numbers of reproducible peaks for EVEN were
extrapolated from the ODD condition. This gave a conservative result of 736 peaks
and an optimal result of 905 peaks for both conditions, although any peaks called
in intron areas were then subsequently removed, as these are most likely errors
arising from an incorrect peak shift.
Motif ﬁnding. We used the meme-chip programme for motif ﬁnding. As input
for meme-chip we used a region of 250 bp ﬂanking each peak summit, for a total of
501 bp long sequences extracted from both ODD and EVEN peak lists. To prevent
biases between the sizes of the two sets, sequences were randomly extracted from
the larger set (EVEN) until the size of the smaller (ODD) was reached. Default
parameters were used except that ‘-norc’ was used. This option prevents the
programme from searching the reverse complement, which is irrelevant here as the
sequences under consideration are single-stranded RNA.
RNA immunoprecipitation. HCT116 cells were cross-linked using 1500 mJ cm 2
and collected in cold PBS. Fifty millions cells per samples were subjected to
nuclear/cytoplasmic fractionation using Nuclei EZ Lysis Buffer (Sigma), cyto-
plasmic fractions were collected and the volume adjusted in 2 polysome buffer
(Tris–Cl pH 7.4 20mM, NaCl 200mM, MgCl2 2.5mM, Triton-X 1%, DTT 1mM,
protease inhibitor cocktail, Superase-In). Lysates were pre-cleared with yeast RNA
(0.1mgml 1) and recombinant protein G agarose (Thermo Scientiﬁc) for 30min
at 4 C. One per cent of the sample were used as input, the remaining samples
incubated with STAU1 antibody (Proteintech, 14225-1-AP) or IgG from rabbit
serum (I5006, Sigma) overnight at 4 C, The RNA-antibody complexes were
collected by incubation with Dynabeads protein G beads (Invitrogen). The samples
were washed four times and Proteinase K treated before the RNA was extracted for
qRT–PCR analysis.
RNA–RNA interaction prediction. Thermodynamic stable interaction sites of
SNHG5 (ENST00000414002), the 30 UTR of SPATS2 (NM 001293285.1) and the
30 UTR of GLE1 (NM 001003722.1) were predicted with IntaRNA (version 1.2.5;
default parameters)38. The interaction sites of lowest energy with SPATS2
( 15.50 kcalmol 1) and GLE1 ( 14.7 kcalmol 1) span the exons 1 and 2 of
SNHG5. The conservation of the interaction site was tested with PETcofold
(version 3.2; maximal percentage of gaps in alignment column -g is set to 0.5)39.
The transcript alignments were extracted from the genome-wide hg19 46way
multiz alignments. We used the ‘Stitch MAF blocks’ function of the Galaxy browser
to get a connected alignment for each exon, removed all sequences with more than
50% gaps from the alignments, and concatenated exons of the species that occurred
in all exons.
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Statistical testing. All P values are calculated using a two-tailed Student’s
t-test, unless otherwise stated. For the analysis of the growth curves from the
xenograft experiment, the following method was applied: Categoric variables
were reported by means of contingency tables. Furthermore, for continuous
variables, median and range were computed. To investigate their associations
with the product and group parameters, univariate statistical analyses were
performed using Kruskal–Wallis or Mann–Whitney non-parametric test. More-
over, multivariate analyses were carried out. Linear mixed-regression model,
containing both ﬁxed and random effects, was used to determine the relationship
between luminescence growth and number of days after injection. The ﬁxed part
of the model included variables corresponding to the number of post-injection
days and the different product treatments. Interaction terms were built into the
model; random intercepts and random slopes were included to take time into
account. The coefﬁcients of the model were estimated by maximum likelihood
and considered signiﬁcant at the 0.05 levels. The power of analysis was reduced
because of the limited number of xenograft tumours and few tumours did not
have measurements for all variables. All P values reported are two sided and the
signiﬁcance level was set at 5% (Po0.05) Statistical analysis was performed
using the STATA 13 software (Stata Corporation, College Station, TX, USA).
Data availability. The datasets generated during and/or analysed during the
current study are available: the CRC microarray data: GSE76713. The CRC
RNA-seq data: Supplementary Table 4. The RNA-seq data from HCT116 cells
with knockdown of SNHG5: GSE76801. The RIA-seq data from HCT116 cells for
SNHG5: GSE76792.
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